Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential afatinib plus chemotherapy followed by osimertinib plus chemotherapy in untreated EGFR-mutant NSCLC
2020-003025-37Phase 2Completed
- Sponsor
- VU University Medical Center
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and osimertinib in non-small cell lung cancer (NSCLC), sponsored by VU University Medical Center. Primary endpoint: Disease control rate at 18 months. Started Oct 2020; status: completed.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003025-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003025-37.